4D Molecular Therapeutics FDMT Unpaid Stock Issuance Costs In Accrued And Other Liabilities
Unpaid Stock Issuance Costs In Accrued And Other Liabilities at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept fdmt:UnpaidStockIssuanceCostsInAccruedAndOtherLiabilities.
The official record: 4D Molecular Therapeutics’s 10-K, filed March 18, 2026, on SEC EDGAR. View the filing →
Ask your AI about 4D Molecular Therapeutics's unpaid stock issuance costs in accrued and other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 4D Molecular Therapeutics's unpaid stock issuance costs in accrued and other liabilities?
- 4D Molecular Therapeutics (FDMT) reported unpaid stock issuance costs in accrued and other liabilities of $76.75K in Q4 2025.
- What does unpaid stock issuance costs in accrued and other liabilities mean?
- Represents costs associated with the issuance of equity that have been incurred but not yet paid in cash at the end of the reporting period. These costs are typically recorded as liabilities until the settlement date. Monitoring this helps investors understand pending cash outflows related to past financing activities.